Tuberculosis Testing
EDM number 1346 in 2005-06, proposed by Ian Gibson on 11/01/2006.
That this House notes with concern that the prevalence of tuberculosis (TB) in the United Kingdom has risen by 33 per cent.; further notes that the tuberculin skin test for latent TB infection was developed 115 years ago and is inaccurate in up to 50 per cent. of cases; observes that the new T-SPOT blood test for TB delivers a 96.3 per cent. sensitivity rate, reducing missed TB cases, morbidity and higher costs of treating subsequent disease; further observes that the T-SPOT blood test requires only one visit to hospital, avoiding gaps in detection and treatment as a result of up to one-third of patients failing to attend the second visit required for skin testing; further notes that the Government's 2004 TB Action Plan identifies accurate diagnosis using technological advances as one of the key priorities for the control of TB; further observes that the National Institute for Health and Clinical Excellence (NICE) appears in its draft guidance on TB testing to have reflected neither the potential savings of £7,000 for every additional case of TB averted through use of the blood test, nor the improved quality of life of patients; further observes that the alternative Mantoux skin test being considered would require substantial retraining of healthcare personnel and is unlicensed for use in the United Kingdom; and calls upon the Department of Health and NICE to review current testing policy and promote greater adoption of the T-SPOT blood test as the most effective procedure.
This motion has been signed by a total of 97 MPs.
Download raw data as csv or xml.